Cargando…
Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation
Cancer immunotherapy, as a new treatment modality, has been shown to be effective, especially in metastatic melanoma and lung cancer. Organ transplantation can be a life-saving procedure for patients with end-stage diseases of lung, heart, kidney and liver. While ironically, as improvements in organ...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732630/ https://www.ncbi.nlm.nih.gov/pubmed/29302641 http://dx.doi.org/10.1097/IJ9.0000000000000049 |
_version_ | 1783286742281879552 |
---|---|
author | Liu, Mengqi Guo, Wenzhi Zhang, Shuijun |
author_facet | Liu, Mengqi Guo, Wenzhi Zhang, Shuijun |
author_sort | Liu, Mengqi |
collection | PubMed |
description | Cancer immunotherapy, as a new treatment modality, has been shown to be effective, especially in metastatic melanoma and lung cancer. Organ transplantation can be a life-saving procedure for patients with end-stage diseases of lung, heart, kidney and liver. While ironically, as improvements in organ transplantation have extended patients’ lives, new or recurrent postsurgical malignancies have become an increasing threat to their long-term survival, especially in patients after liver transplantation due to hepatocellular carcinoma. The feasibility of immunotherapy treatment for such patients is still to be investigated. |
format | Online Article Text |
id | pubmed-5732630 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Wolters Kluwer |
record_format | MEDLINE/PubMed |
spelling | pubmed-57326302018-01-02 Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation Liu, Mengqi Guo, Wenzhi Zhang, Shuijun Int J Surg Oncol (N Y) Review Articles Cancer immunotherapy, as a new treatment modality, has been shown to be effective, especially in metastatic melanoma and lung cancer. Organ transplantation can be a life-saving procedure for patients with end-stage diseases of lung, heart, kidney and liver. While ironically, as improvements in organ transplantation have extended patients’ lives, new or recurrent postsurgical malignancies have become an increasing threat to their long-term survival, especially in patients after liver transplantation due to hepatocellular carcinoma. The feasibility of immunotherapy treatment for such patients is still to be investigated. Wolters Kluwer 2017-12 2017-11-16 /pmc/articles/PMC5732630/ /pubmed/29302641 http://dx.doi.org/10.1097/IJ9.0000000000000049 Text en Copyright © 2017 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of IJS Publishing Group Ltd. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License 4.0 (http://creativecommons.org/licenses/by/4.0/) (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Review Articles Liu, Mengqi Guo, Wenzhi Zhang, Shuijun Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation |
title | Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation |
title_full | Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation |
title_fullStr | Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation |
title_full_unstemmed | Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation |
title_short | Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation |
title_sort | cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732630/ https://www.ncbi.nlm.nih.gov/pubmed/29302641 http://dx.doi.org/10.1097/IJ9.0000000000000049 |
work_keys_str_mv | AT liumengqi cancerimmunotherapyinpatientswithneworrecurrentmalignanciesafterlivertransplantation AT guowenzhi cancerimmunotherapyinpatientswithneworrecurrentmalignanciesafterlivertransplantation AT zhangshuijun cancerimmunotherapyinpatientswithneworrecurrentmalignanciesafterlivertransplantation |